Bristol-Myers Lung Cancer Drug Did Not Meet Primary Endpoint In Late-stage Trial

Bristol-Myers Squibb Co. shares plummeted as much as 19.0% in pre-market trade Friday after the company said its non-small cell lung cancer drug did not meet its primary endpoint in a phase 3 clinical trial.